Pricing furor won't burst biotech bubble, Orbimed partner says; Enterome inks an oncology deal;

@FierceBiotech: Soon-Shiong's NantKwest is spending more on stock buybacks than R&D. Report | Follow @FierceBiotech

@JohnCFierce: Anacetrapib will be either the best come-from-behind PhIII victory or an awfully expensive new cautionary tale about R&D hubris. Hmmmm. | Follow @JohnCFierce

@DamianFierce: Tough day at the Robert J. Coury Global Center, on 1000 Mylan Blvd. More from the WSJ | Follow @DamianFierce

> Political pressure on drug pricing is unlikely to burst the biotech bubble, according to Orbimed Advisors' Sven Borho, saying the odds of policy changes in the U.S. are "extremely remote." More

> France's Enterome Bioscience signed a deal with cancer center Gustave Roussy to explore how microbiomics can play a role in oncology. News

> Roche ($RHHBY) is shutting down four manufacturing facilities as it moves toward specialty medicines. Story

Medical Device News

@FierceMedDev: Resurgent 23andMe CEO says the genetic testing company is not up for sale. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Boston Sci's Watchman hit by restrictive CMS coverage decision, recall over blood leakage. Story | Follow @VarunSaxena2

@EmilyWFierce: Women are suing Endo Health Solutions and Patheon for child support after contraceptive packaging mishap. FiercePharmaManufacturing story | Follow @EmilyWFierce

> Startup gets $14.3M from U.S. military to eliminate imaging in large vessel trauma procedure. Story

> GE Healthcare partners with an Oregon university for cardiovascular research. News

> Medical marijuana startup develops Keurig-like vaporizer device. Article

Pharma News

@FiercePharma: Aratana unveils branding and partnering plans at investor day. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI:  whacking 1,200 jobs, closing plants in US, Ireland, Italy and Spain, but building one in Switzerland. Article | Follow @EricPFierce

@CarlyHFierce: Boehringer ups the ante in IPF drug race with awareness funding. FiercePharmaMarketing report | Follow @CarlyHFierce

> Regeneron expanding New York campus again, adding 300 jobs. More

> Gilead scores additional indications for Harvoni in hep C, HIV patients. Story

> Analysts improve outlook for Teva's Copaxone as it shakes off Novartis competition. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.